股息配發率   玩股撇步(動畫小學堂)

  • 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
  • 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
  • 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY現金股利 YoY股票股利 YoY現金配發率 YoY股票配發率 YoY全部配發率 YoY
2023 (10)-1.8200.0000.0000.0000.0000.000
2022 (9)-1.2200.0000.0000.0000.0000.000
2021 (8)0.5100.0000.0000.0000.0000.000
2020 (7)-1.3800.0000.0000.0000.0000.000
2019 (6)-0.6000.0000.0000.0000.0000.000
2018 (5)-0.4100.0000.0000.0000.0000.000
2017 (4)-3.4800.0000.0000.0000.0000.000
2016 (3)-5.9500.0000.0000.0000.0000.000
每股盈餘-近20季
EPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY
24Q3 (20)-0.4330.6525.86-0.4227.592.33-1.66-32.8-39.5
24Q2 (19)-0.620.0-313.33-0.58-31.82-205.26-1.25-101.61-104.92
24Q1 (18)-0.621.59-34.78-0.44-25.71-25.71-0.6265.93-34.78
23Q4 (17)-0.63-8.62-270.59-0.3518.6-218.18-1.82-52.94-49.18
23Q3 (16)-0.58-286.67-544.44-0.43-126.32-330.0-1.19-95.08-13.33
23Q2 (15)-0.1567.3965.91-0.1945.7147.22-0.61-32.6137.11
23Q1 (14)-0.46-170.5913.21-0.35-218.1820.45-0.4662.313.21
22Q4 (13)-0.17-88.89-183.33-0.11-10.0-1200.0-1.22-16.19-339.22
22Q3 (12)-0.0979.5535.71-0.1072.22-66.67-1.05-8.25-284.21
22Q2 (11)-0.4416.98-158.67-0.3618.180.0-0.97-83.02-236.62
22Q1 (10)-0.53-783.33-960.0-0.44-4500.0-158.82-0.53-203.92-960.0
21Q4 (9)-0.0657.140.00.01116.67105.880.51-10.53136.96
21Q3 (8)-0.14-118.6778.46-0.0683.3381.250.57-19.72143.18
21Q2 (7)0.751600.0270.45-0.36-111.76-44.00.711520.0204.41
21Q1 (6)-0.0516.6778.26-0.170.019.05-0.0596.3878.26
20Q4 (5)-0.0690.7785.37-0.1746.8822.73-1.38-4.55-130.0
20Q3 (4)-0.65-47.730.0-0.32-28.00.0-1.32-94.120.0
20Q2 (3)-0.44-91.30.0-0.25-19.050.0-0.68-195.650.0
20Q1 (2)-0.2343.90.0-0.214.550.0-0.2361.670.0
19Q4 (1)-0.410.00.0-0.220.00.0-0.600.00.0
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2024/110.29-45.188.893.422.851.17N/A-
2024/100.5352.0458.313.0923.71.34N/A本月營收主要因中國市場消費力提升,故營業收入較去年同期增加
2024/90.35-24.423.922.5618.351.040.54-
2024/80.4699.19337.922.2120.990.930.6本月營收主要因中國市場消費力提升,故營業收入較去年同期增加
2024/70.23-4.8771.261.751.650.730.77本月營收因中國市場消費力提升,故營業收入漸趨回穩
2024/60.24-4.58-18.181.52-4.260.90.58-
2024/50.25-36.22-45.261.28-1.060.950.55-
2024/40.436.2546.181.0223.860.790.66-
2024/30.29201.1946.180.6212.810.620.82-
2024/20.1-58.1-52.950.33-6.220.491.03本月營收,因中國疫情後整體消費力道減弱影響,故營業收入較去年同期大幅減少
2024/10.2342.3360.590.2360.590.660.77本月營收,因中國疫情後整體消費力道減弱影響,故營業收入較去年同期大幅減少
2023/120.16-38.7219.362.93-16.350.760.59-
2023/110.27-20.3-42.522.76-17.80.940.48-
2023/100.33-0.19-29.292.5-13.850.770.58-
2023/90.33218.45-14.052.16-10.840.580.99-
2023/80.11-22.1-70.471.83-10.220.541.06本月營收主要因中國市場消費力下降,故營業收入較去年同期減少
2023/70.14-54.55-64.491.722.540.90.64本月營收,因中國市場主要消費力下降,故營業收入較去年同期減少
2023/60.3-36.17-16.341.5922.151.040.42-
2023/50.4770.3480.581.2936.620.940.46本月營收,因中國疫情解封影響,故營業收入較去年同期大幅增加
2023/40.2736.25629.580.8320.130.680.63本月營收,因中國疫情解封影響,故營業收入較去年同期大幅增加
2023/30.2-3.06-4.260.55-15.00.551.07-
2023/20.2142.9938.260.35-20.110.491.21-
2023/10.145.79-50.180.14-50.180.740.79本月營收,因中國疫情解封影響,故營業收入較去年同期大幅減少
2022/120.14-70.49-58.433.5-12.41.070.59本月營收,因中國疫情解封影響,故營業收入較去年同期大幅減少
2022/110.46-1.95-14.713.36-8.271.330.48-
2022/100.4721.32-34.982.9-7.151.220.52-
2022/90.399.4-38.332.431.291.130.66-
2022/80.36-6.33-27.72.0415.491.090.68-
2022/70.387.075.71.6832.240.990.75-
2022/60.3637.79-40.321.342.720.651.48-
2022/50.26588.22537.650.94199.310.51.9本月營收,因對轉投資ACIM持有股權達100%,故將ACIM之5月營收合併納入,故造成整體營收大幅上升
2022/40.04-82.12-31.030.69149.620.42.42本月營收,因受中國疫情封城影響,故營業收入較去年同期大幅減少
2022/30.2139.99228.20.65194.020.651.45本月營收,因對轉投資ACIM持有股權達100%,故將ACIM之3月營收合併納入,故造成整體營收大幅上升
2022/20.15-48.48345.820.44180.140.771.22本月營收,因對轉投資ACIM持有股權達100%,故將ACIM之2月營收合併納入,故造成整體營收大幅上升
2022/10.29-11.73135.120.29135.121.160.81本月營收,因對轉投資ACIM持有股權達100%,故將ACIM之1月營收合併納入,故造成整體營收大幅上升
2021/120.33-39.4587.923.99165.111.60.61本月營收,因對轉投資ACIM持有股權達51%,故將ACIM之12月營收合併納入,故造成整體營收大幅上升
2021/110.54-25.26299.933.67175.261.90.51本月營收,因對轉投資ACIM持有股權達51%,故將ACIM之11月營收合併納入,故造成整體營收大幅上升
2021/100.7315.07995.613.12161.091.850.52本月營收,因對轉投資ACIM持有股權達51%,故將ACIM之9月營收合併納入,故造成整體營收大幅上升
2021/90.6328.25429.932.4112.051.480.59本月營收,因對轉投資ACIM持有股權達51%,故將ACIM之9月營收合併納入,故造成整體營收大幅上升
2021/80.4936.95304.721.7674.531.450.6本月營收,因對轉投資ACIM持有股權達51%,故將ACIM之8月營收合併納入,故造成整體營收大幅上升
2021/70.36-39.55211.691.2742.991.00.87本月營收,因對轉投資ACIM持有股權達51%,故將ACIM之7月營收合併納入,故造成整體營收大幅上升
2021/60.61372.291775.510.9117.810.691.26本月營收,因對轉投資ACIM持有股權達51%,故將ACIM之6月營收合併納入,故造成整體營收大幅上升
2021/50.04-25.56-28.580.32-57.420.165.49本月營收受中國肺炎疫情影響,市場消費力道衰退,故造成營收下滑
2021/40.05-14.91-83.120.28-59.80.155.74因市場產能過剩,公司採取保守策略接單所致
2021/30.0690.16-72.890.22-39.140.220.41因市場產能過剩,公司採取保守策略接單所致
2021/20.03-72.8318.710.1623.170.330.27-
2021/10.12-29.4524.440.1224.440.430.21-
2020/120.1828.84-56.281.51-62.760.380.27因今年肺炎疫情影響接單狀況不佳,造成今年當月營收偏低
2020/110.14104.74-88.071.33-63.470.320.31因今年肺炎疫情影響接單狀況不佳,造成今年當月營收偏低
2020/100.07-44.33-86.531.2-52.280.310.33因今年肺炎疫情影響接單狀況不佳,造成今年當月營收偏低
2020/90.12-2.04-71.61.13-43.90.360.25因今年肺炎疫情影響接單狀況不佳,造成今年當月營收偏低
2020/80.125.47-75.951.01-36.60.270.33因今年肺炎疫情影響接單狀況不佳,造成今年當月營收偏低
2020/70.12263.72-46.720.89-18.260.20.44本月營收受中國肺炎疫情影響,市場消費力道衰退,故造成營收下滑
2020/60.03-43.93-70.750.77-11.180.410.27本月營收受中國肺炎疫情影響,市場消費力道衰退,故造成營收下滑
2020/50.06-82.4-64.970.74-2.70.610.18本月營收受中國肺炎疫情影響,市場消費力道衰退,故造成營收下滑
2020/40.3236.639.860.6814.060.590.19-
2020/30.24732.8912.550.3618.060.360.3-
2020/20.03-71.5116.760.1329.80.530.21-
2020/10.1-75.2134.060.134.060.0N/A-
2019/120.4-64.85306.044.05306.620.0N/A因去年同月接單狀況不佳,基數較低,造成今年本月增加幅度偏高

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。